Laboratory Medicine ›› 2025, Vol. 40 ›› Issue (12): 1171-1176.DOI: 10.3969/j.issn.1673-8640.2025.12.006
ZHEN Di, JIA Bin, MENG Xianyi
Received:2024-05-11
Revised:2025-04-14
Online:2025-12-30
Published:2025-12-26
CLC Number:
ZHEN Di, JIA Bin, MENG Xianyi. Roles of serum sPD-1 and sTWEAK levels in patients with ulcerative colitis in disease monitoring and prognosis assessment[J]. Laboratory Medicine, 2025, 40(12): 1171-1176.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2025.12.006
| 组别 | 例数 | sPD-1/(ng·mL-1) | sTWEAK/(pg·mL-1) |
|---|---|---|---|
| 正常对照组 | 57 | 14.67±3.18 | 26.35±6.94 |
| 缓解组 | 31 | 15.07±4.36 | 30.29±8.36 |
| 轻度组 | 18 | 20.84±5.33*# | 37.92±8.95*# |
| 中度组 | 28 | 26.72±6.89*#△ | 48.71±9.60*#△ |
| 重度组 | 13 | 32.14±8.35*#△▲ | 59.35±10.37*#△▲ |
| F值 | 31.314 | 38.495 | |
| P值 | <0.001 | <0.001 |
| 组别 | 例数 | sPD-1/(ng·mL-1) | sTWEAK/(pg·mL-1) |
|---|---|---|---|
| 正常对照组 | 57 | 14.67±3.18 | 26.35±6.94 |
| 缓解组 | 31 | 15.07±4.36 | 30.29±8.36 |
| 轻度组 | 18 | 20.84±5.33*# | 37.92±8.95*# |
| 中度组 | 28 | 26.72±6.89*#△ | 48.71±9.60*#△ |
| 重度组 | 13 | 32.14±8.35*#△▲ | 59.35±10.37*#△▲ |
| F值 | 31.314 | 38.495 | |
| P值 | <0.001 | <0.001 |
| 组别 | 例数 | sPD-1/(ng·mL-1) | sTWEAK/(pg· mL-1) |
|---|---|---|---|
| 非复发组 | 50 | 18.36±4.65 | 37.82±6.94 |
| 复发组 | 40 | 27.25±8.49 | 46.64±9.06 |
| t值 | 6.319 | 5.230 | |
| P值 | <0.001 | <0.001 |
| 组别 | 例数 | sPD-1/(ng·mL-1) | sTWEAK/(pg· mL-1) |
|---|---|---|---|
| 非复发组 | 50 | 18.36±4.65 | 37.82±6.94 |
| 复发组 | 40 | 27.25±8.49 | 46.64±9.06 |
| t值 | 6.319 | 5.230 | |
| P值 | <0.001 | <0.001 |
| 组别 | 例数 | 性别 | 年龄/岁 | 体重指数/(kg·m-2) | 病程/月 | CRP/(mg·L-1) | 红细胞沉降率/(mm·h-1) | ||
|---|---|---|---|---|---|---|---|---|---|
| 男/例 | 女/例 | ||||||||
| 非复发组 | 50 | 34 | 16 | 42.03±7.33 | 24.11±5.95 | 10.32±2.37 | 10.86±2.59 | 34.15±4.79 | |
| 复发组 | 40 | 23 | 17 | 41.31±7.82 | 23.97±5.69 | 10.55±2.59 | 22.34±2.43 | 35.64±4.83 | |
| 统计值 | 1.055 | 0.449 | 0.113 | 0.439 | 21.472 | 1.461 | |||
| P值 | 0.304 | 0.654 | 0.910 | 0.662 | <0.001 | 0.148 | |||
| 组别 | 病变部位 | 吸烟史/例 | 饮酒史/例 | TNF-α/(ng·L-1) | 白细胞计数/(×109L-1) | ||||
| 直肠/例 | 左半结肠/例 | 广泛结肠/例 | |||||||
| 非复发组 | 4 | 14 | 32 | 9 | 8 | 20.89±2.41 | 4.45±0.51 | ||
| 复发组 | 3 | 11 | 26 | 11 | 13 | 33.02±2.75 | 4.46±0.59 | ||
| 统计值 | 0.013 | 1.160 | 3.382 | 22.282 | 0.086 | ||||
| P值 | 0.994 | 0.281 | 0.066 | <0.001 | 0.932 | ||||
| 组别 | 例数 | 性别 | 年龄/岁 | 体重指数/(kg·m-2) | 病程/月 | CRP/(mg·L-1) | 红细胞沉降率/(mm·h-1) | ||
|---|---|---|---|---|---|---|---|---|---|
| 男/例 | 女/例 | ||||||||
| 非复发组 | 50 | 34 | 16 | 42.03±7.33 | 24.11±5.95 | 10.32±2.37 | 10.86±2.59 | 34.15±4.79 | |
| 复发组 | 40 | 23 | 17 | 41.31±7.82 | 23.97±5.69 | 10.55±2.59 | 22.34±2.43 | 35.64±4.83 | |
| 统计值 | 1.055 | 0.449 | 0.113 | 0.439 | 21.472 | 1.461 | |||
| P值 | 0.304 | 0.654 | 0.910 | 0.662 | <0.001 | 0.148 | |||
| 组别 | 病变部位 | 吸烟史/例 | 饮酒史/例 | TNF-α/(ng·L-1) | 白细胞计数/(×109L-1) | ||||
| 直肠/例 | 左半结肠/例 | 广泛结肠/例 | |||||||
| 非复发组 | 4 | 14 | 32 | 9 | 8 | 20.89±2.41 | 4.45±0.51 | ||
| 复发组 | 3 | 11 | 26 | 11 | 13 | 33.02±2.75 | 4.46±0.59 | ||
| 统计值 | 0.013 | 1.160 | 3.382 | 22.282 | 0.086 | ||||
| P值 | 0.994 | 0.281 | 0.066 | <0.001 | 0.932 | ||||
| 项目 | sPD-1 | sTWEAK | |||
|---|---|---|---|---|---|
| r值 | P值 | r值 | P值 | ||
| CRP | 0.434 | <0.001 | 0.418 | <0.001 | |
| TNF-α | 0.405 | <0.001 | 0.423 | <0.001 | |
| 项目 | sPD-1 | sTWEAK | |||
|---|---|---|---|---|---|
| r值 | P值 | r值 | P值 | ||
| CRP | 0.434 | <0.001 | 0.418 | <0.001 | |
| TNF-α | 0.405 | <0.001 | 0.423 | <0.001 | |
| 项目 | AUC(95%CI①) | 最佳临界值 | 敏感性/% | 特异性/% | Youden指数 |
|---|---|---|---|---|---|
| sPD-1 | 0.789(0.690~0.868) | 24.76 ng·mL-1 | 62.50 | 88.00 | 0.505 |
| sTWEAK | 0.752(0.650~0.837) | 39.33 pg·mL-1 | 75.00 | 72.00 | 0.470 |
| sPD-1+sTWEAK | 0.866(0.778~0.929) | 0.49 | 82.50 | 70.00 | 0.525 |
| CRP | 0.707(0.602~0.798) | 16.23 mg·L-1 | 75.00 | 62.00 | 0.370 |
| TNF-α | 0.664(0.557~0.760) | 26.48 ng·L-1 | 60.00 | 72.00 | 0.320 |
| 项目 | AUC(95%CI①) | 最佳临界值 | 敏感性/% | 特异性/% | Youden指数 |
|---|---|---|---|---|---|
| sPD-1 | 0.789(0.690~0.868) | 24.76 ng·mL-1 | 62.50 | 88.00 | 0.505 |
| sTWEAK | 0.752(0.650~0.837) | 39.33 pg·mL-1 | 75.00 | 72.00 | 0.470 |
| sPD-1+sTWEAK | 0.866(0.778~0.929) | 0.49 | 82.50 | 70.00 | 0.525 |
| CRP | 0.707(0.602~0.798) | 16.23 mg·L-1 | 75.00 | 62.00 | 0.370 |
| TNF-α | 0.664(0.557~0.760) | 26.48 ng·L-1 | 60.00 | 72.00 | 0.320 |
| 因素 | β值 | 标准误 | Wald值 | P值 | OR①值(95%CI) |
|---|---|---|---|---|---|
| CRP | 0.204 | 0.056 | 13.239 | <0.001 | 1.226(1.099~1.368) |
| TNF-α | 0.324 | 0.154 | 4.433 | 0.035 | 1.383(1.023~1.870) |
| sPD-1 | 0.460 | 0.163 | 7.963 | 0.005 | 1.584(1.151~2.180) |
| sTWEAK | 0.527 | 0.185 | 8.099 | 0.004 | 1.693(1.178~2.433) |
| 因素 | β值 | 标准误 | Wald值 | P值 | OR①值(95%CI) |
|---|---|---|---|---|---|
| CRP | 0.204 | 0.056 | 13.239 | <0.001 | 1.226(1.099~1.368) |
| TNF-α | 0.324 | 0.154 | 4.433 | 0.035 | 1.383(1.023~1.870) |
| sPD-1 | 0.460 | 0.163 | 7.963 | 0.005 | 1.584(1.151~2.180) |
| sTWEAK | 0.527 | 0.185 | 8.099 | 0.004 | 1.693(1.178~2.433) |
| [1] | 王春霞, 葛俊李, 李芳, 等. 中药治疗溃疡性结肠炎作用及机制研究进展[J]. 中国实验方剂学杂志, 2023, 29(2):270-282. |
| [2] |
GAJENDRAN M, LOGANATHAN P, JIMENEZ G, et al. A comprehensive review and update on ulcerative colitis[J]. Dis Mon, 2019, 65(12):100851.
DOI URL |
| [3] |
GROS B, KAPLAN G G. Ulcerative colitis in adults:a review[J]. JAMA, 2023, 330(10):951-965.
DOI URL |
| [4] |
KAENKUMCHORN T, WAHBEH G. Ulcerative colitis:making the diagnosis[J]. Gastroenterol Clin North Am, 2020, 49(4):655-669.
DOI URL |
| [5] |
石鹏辉, 范伟光, 张珍, 等. CXCR5、sPD-1、Hcy在AIDS患者治疗过程中的动态变化及临床意义[J]. 检验医学, 2022, 37(2):103-107.
DOI |
| [6] |
BERNARDI S, VOLTAN R, RIMONDI E, et al. TRAIL,OPG,and TWEAK in kidney disease:biomarkers or therapeutic targets?[J]. Clin Sci(Lond), 2019, 133(10):1145-1166.
DOI URL |
| [7] | ZAITSEVA O, HOFFMANN A, OTTO C, et al. Targeting fibroblast growth factor(FGF)-inducible 14(Fn14)for tumor therapy[J]. Front Pharmacol, 2022,13:935086. |
| [8] | 中华医学会消化病学分会炎症性肠病学组. 炎症性肠病诊断与治疗的共识意见(2018年·北京)[J]. 中华炎性肠病杂志(中英文), 2018, 2(3):173-190. |
| [9] |
SZÉLES Á, FAZEKAS T, VÁNCSA S, et al. Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy:a systematic review and meta-analysis[J]. Cancer Immunol Immunother, 2023, 72(5):1061-1073.
DOI |
| [10] | WU D, LIU Y, PANG N, et al. PD-1/PD-L1 pathway activation restores the imbalance of Th1/Th2 and treg/Th17 cells subtypes in immune thrombocytopenic purpura patients[J]. Medicine(Baltimore), 2019, 98(43):e17608. |
| [11] | BRUNET-RATNASINGHAM E, MOROU A, DUBÉ M, et al. Immune checkpoint expression on HIV-specific CD4+ T cells and response to their blockade are dependent on lineage and function[J]. EBioMedicine, 2022,84:104254. |
| [12] | 谭宁, 刘建湘, 亢倩, 等. 慢性乙型肝炎临床治愈者的血清sPD-1和sPD-L1水平及临床特点[J]. 临床肝胆病杂志, 2023, 39(1):50-55. |
| [13] | GUO Y, REN M, GE L, et al. Increased serum concentrations of TNF-like weak inducer of apoptosis predict higher 28-day mortality in patients with sepsis[J]. Emerg Med Int, 2019,2019:7238705. |
| [14] |
DA SILVA-CANDAL A, CUSTODIA A, LÓPEZ-DEQUIDT I, et al. sTWEAK is a leukoaraiosis biomarker associated with neurovascular angiopathy[J]. Ann Clin Transl Neurol, 2022, 9(2):171-180.
DOI URL |
| [15] | 张鑫, 王慧, 刘肃, 等. 两种血清指标联合检测对非心脏手术围术期心脏不良事件发生的预测价值分析[J]. 中华老年心脑血管病杂志, 2021, 23(11):1177-1179. |
| [16] | COMERTPAY E, VURAL S, EROĞLU O, et al. The diagnostic value of sTWEAK in acute ischemic stroke[J]. Balkan Med J, 2020, 37(6):336-340. |
| [17] |
MIRIOGLU S, CINAR S, YAZICI H, et al. Serum and urine TNF-like weak inducer of apoptosis,monocyte chemoattractant protein-1 and neutrophil gelatinase-associated lipocalin as biomarkers of disease activity in patients with systemic lupus erythematosus[J]. Lupus, 2020, 29(4):379-388.
DOI URL |
| [18] |
MA H Y, CHEN S, CAO W D, et al. Diagnostic value of TWEAK for predicting active lupus nephritis in patients with systemic lupus erythematosus:a systematic review and meta-analysis[J]. Ren Fail, 2021, 43(1):20-31.
DOI URL |
| [1] | DAI Jingwen, YANG Shuo, WANG Chong, SUN Lin, GU Meixiu, XIAN Jingrong, PAN Baishen, WANG Beili, ZHANG Chunyan, GUO Wei. Role of preoperative mean corpuscular hemoglobin concentration for predicting postoperative recurrence in intrahepatic cholangiocarcinoma patients [J]. Laboratory Medicine, 2025, 40(4): 344-349. |
| [2] | LIU Yi, SU Xiaoming, WANG Yuanyuan, JU Tao. Roles of serum L-Arg and IL-4 levels in predicting recurrent ischemic stroke in patients with symptomatic carotid artery stenosis [J]. Laboratory Medicine, 2024, 39(7): 634-639. |
| [3] | DING Jing, ZHANG Chunling, WANG Xiaorui, LI Huidan, WANG Hongling, LIU Weiling, LIN Lihui, LI Li. Laboratory diagnosis and prognostic factor analysis of core binding factor-related acute myeloid leukemia [J]. Laboratory Medicine, 2024, 39(7): 673-681. |
| [4] | GU Liangliang, WANG Jianfeng, QIAO Xin, ZHANG Baochao, FU Guohui. Correlation between serum LRG1 level and cognitive impairment and recurrence in patients with acute ischemic stroke [J]. Laboratory Medicine, 2024, 39(5): 443-448. |
| [5] | SHEN Zhan, BIAN Xiaobo, HUANG Ying, WANG Siyang, SHEN Tingting, ZHANG Xian, SONG Yunxiao, XIE Lianhong. Stroke recurrence prediction model based on machine learning algorithms using routine blood test [J]. Laboratory Medicine, 2024, 39(12): 1190-1195. |
| [6] | LIANG Chunfang, ZHU Kangning, ZHANG Qi. Serum miR-21 and miR-135a expression levels in predicting the recurrence and metastasis of gastric cancer patients after chemotherapy [J]. Laboratory Medicine, 2022, 37(5): 417-422. |
| [7] | ZHENG Yu, CHEN Jin. Correlation between serum follistatin and clinicopathological characteristics and prognosis of patients with differentiated thyroid cancer [J]. Laboratory Medicine, 2022, 37(11): 1066-1070. |
| [8] | MAO Zheng, QIAN Zengkun, YING Fei, WANG Zhaoli, XIAO Qun, CUI Fan. Correlation between E-Cad,G-17,HER-2 and postoperative recurrence risk of gastric cancer [J]. Laboratory Medicine, 2022, 37(1): 41-46. |
| [9] | LIN Jiafei, CHEN Xiaosong, WU Beiying, CAI Gang, LIN Lin. 21-Gene recurrence score in mucinous breast cancer [J]. Laboratory Medicine, 2021, 36(7): 714-718. |
| [10] | LUO Ting, PAN Xiujun. Research progress on neutrophil extracellular traps in ulcerative colitis [J]. Laboratory Medicine, 2020, 35(6): 626-630. |
| [11] | JIN Fangfang, JIN Zizheng, LIU Ning, LOU Jinli. Changes of CD3bright T lymphocytes in patients with hepatocellular carcinoma before and after recurrence [J]. Laboratory Medicine, 2020, 35(3): 209-213. |
| [12] | ZENG Junxiang, HUANG Yilei, GE Wensong, PAN Xiujun, SHEN Lisong. Role of aANCA in the evaluation of ulcerative colitis [J]. Laboratory Medicine, 2019, 34(9): 815-820. |
| [13] | DONG Huan, LIU Xiaoyi, CAI Yanqing, CHEN Xinliang, WANG Xianjing. Difference of the expressions of ER,VEGF and TGF-β1 between multiple EP and single EP patients and their prognosis analysis [J]. Laboratory Medicine, 2019, 34(5): 415-420. |
| [14] | YI Qingqing, YANG Rong, LIANG Dongyu, CHANG Qing. Relationship between P53 expression and the recurrence,metastasis and prognosis of breast cancer patients [J]. Laboratory Medicine, 2019, 34(12): 1107-1110. |
| [15] | YI Qingqing, YANG Rong, LIANG Dongyu, CHANG Qing. Relationship between P53 expression and the recurrence,metastasis and prognosis of breast cancer patients [J]. Laboratory Medicine, 2019, 34(12): 1107-1110. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||